TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33912799

Group type: EXPERIMENTAL
Intervention: escitalopram+golimumab (TNF-α inhibitor)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: escitalopram+calcium tablet+vitamin D (PKC activator)
Number of subjects: 180

Group type: COMPARATOR
Intervention: escitalopram+placebo
Number of subjects: 180
Study: 33912999

Group type: EXPERIMENTAL
Intervention: FOLFIRI regimen
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: FOLFIRINOX regimen
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Co-administration of oxaliplatin
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Direct conversion of NPC into SN-38
Number of subjects: 109
Study: 33913006

Group type: EXPERIMENTAL
Intervention: Complex decongestive physiotherapy (CDP)
Number of subjects: 27
Study: 33913035

Group type: EXPERIMENTAL
Intervention: Debridement
Number of subjects: 15

Group type: COMPARATOR
Intervention: Microfracture
Number of subjects: 15

Group type: COMPARATOR
Intervention: Autologous chondrocyte implantation
Number of subjects: 15
Study: 33913086

Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg once daily
Number of subjects: 641

Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg once daily
Number of subjects: 641

Group type: COMPARATOR
Intervention: Placebo switched to upadacitinib 15 mg once daily at week 24
Number of subjects: 641

Group type: COMPARATOR
Intervention: Placebo switched to upadacitinib 30 mg once daily at week 24
Number of subjects: 641

Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg
Number of subjects: 641

Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg
Number of subjects: 641
Study: 33913104

Group type: EXPERIMENTAL
Intervention: ACV lip patch
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo lip patch
Number of subjects: 25
Study: 33913277

Group type: EXPERIMENTAL
Intervention: Diffusion-Weighted MRI (DW MRI)
Number of subjects: 890

Group type: COMPARATOR
Intervention: Mammography
Number of subjects: 890

Group type: COMPARATOR
Intervention: Ultrasonography
Number of subjects: 890

Group type: COMPARATOR
Intervention: Dynamic Contrast-Enhanced MRI (DCE MRI)
Number of subjects: 890
Study: 33913631

Group type: EXPERIMENTAL
Intervention: Modified coronally advanced tunnel (MCAT) technique with porcine-derived acellular dermal matrix (PADM)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Connective tissue grafting (CTG)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Postoperative pain intensity and pain duration in the first week after surgery with PADM
Number of subjects: 12
Study: 33913819

Group type: EXPERIMENTAL
Intervention: Mindful Steps intervention (includes in-person mind-body exercise classes, educational website, online mind-body videos, and pedometer with step-count feedback and goals)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mindful Steps intervention
Number of subjects: 0
Study: 33914096

Group type: EXPERIMENTAL
Intervention: 40 min physical activity per school day during nine compulsory school years
Number of subjects: 81

Group type: COMPARATOR
Intervention: 60 min physical activity per school week (reference group)
Number of subjects: 81
Study: 33914097

Group type: EXPERIMENTAL
Intervention: Selinexor 100 mg weekly with FLAG-Ida
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Selinexor (60 mg, 80 mg, 100 mg weekly) with FLAG-Ida
Number of subjects: 14
Study: 33914329

Group type: EXPERIMENTAL
Intervention: Remifentanil patient-controlled analgesia (RPCA)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Combined spinal-epidural analgesia (CSEA)
Number of subjects: 161
Study: 33914350

Group type: EXPERIMENTAL
Intervention: Lurbinectedin (3.2 mg/m)
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) administration
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Platelet transfusions
Number of subjects: 244
Study: 33914706

Group type: EXPERIMENTAL
Intervention: IFN-γ treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: anti-PD-1 therapy
Number of subjects: 0
Study: 33915374

Group type: EXPERIMENTAL
Intervention: Cariprazine 1.5 mg/d
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Cariprazine 3 mg/d
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Cariprazine (overall)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study: 33915943

Group type: EXPERIMENTAL
Intervention: Engerix-B
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sci-B-Vac
Number of subjects: 0
Study: 33916077

Group type: EXPERIMENTAL
Intervention: Neutrophil-Lymphocyte Ratio (NLR) changes from baseline to Month 12
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Platelet-Lymphocyte Ratio (PLR) changes from baseline to Month 12
Number of subjects: 0
Study: 33917201

Group type: EXPERIMENTAL
Intervention: Valproic acid (VPA) treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: p53 full-length (FL), p53β and p53γ protein isoforms
Number of subjects: 0
Study: 33917922

Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy de-escalation (ticagrelor replaced with clopidogrel)
Number of subjects: 1803

Group type: COMPARATOR
Intervention: Standard antiplatelet therapy
Number of subjects: 1803

Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy (APT)
Number of subjects: 1803
Study: 33919763

Group type: EXPERIMENTAL
Intervention: Novel Oral Liquid Formulation of 13-
Number of subjects: 0
Study: 33920489

Group type: EXPERIMENTAL
Intervention: Convalescent plasma (CP) infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matched propensity score analysis
Number of subjects: 0
Study: 33921051

Group type: EXPERIMENTAL
Intervention: Single bronchodilation monotherapy
Number of subjects: 764
Study: 33921166

Group type: EXPERIMENTAL
Intervention: Probiotic formulation
Number of subjects: 0
Study: 33921527

Group type: EXPERIMENTAL
Intervention: Karasek questionnaire, sociodemographic questionnaire, Maslach Burnout Inventory scale, Hospital Anxiety, Depression Scale, food intake questionnaire, salivary biomarkers (cortisol, immunoglobulin A, lysozyme)
Number of subjects: 0
Study: 33921867

Group type: EXPERIMENTAL
Intervention: Vitamin K antagonist (VKA)
Number of subjects: 2983

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 2983

Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 2983

Group type: EXPERIMENTAL
Intervention: Vitamin K antagonist (VKA) and Rivaroxaban
Number of subjects: 2983
Study: 33922391

Group type: EXPERIMENTAL
Intervention: FCZ (Fluconazole)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 33922654

Group type: EXPERIMENTAL
Intervention: Oral creatine monohydrate (Cr) at a dose of 2 × 7 g per day for 2 months in conjunction with ongoing therapies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral creatine monohydrate (Cr) at a dose of 2 × 3-5 g per day for 3-6 months (proposed future study)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Creatine supplementation as monotherapy or in conjunction with metformin (future potential use)
Number of subjects: 0
Study: 33923628

Group type: EXPERIMENTAL
Intervention: Aerosolised vaccination with MVA85A
Number of subjects: 2
Study: 33924960

Group type: EXPERIMENTAL
Intervention: Plasma biomarkers (p-tau, NfL, Aβ)
Number of subjects: 90
Study: 33925513

Group type: EXPERIMENTAL
Intervention: Accelerometer-measured daily step counts (mean 10699.8 steps)
Number of subjects: 2524

Group type: EXPERIMENTAL
Intervention: Accelerometer-measured daily step counts
Number of subjects: 2524
Study: 33926171

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation ablation
Number of subjects: 5000000

Group type: EXPERIMENTAL
Intervention: Atrial flutter ablation
Number of subjects: 5000000
Study: 33926412

Group type: EXPERIMENTAL
Intervention: Weight-management camp followed by a community intervention (10-week program of weekly lifestyle education and physical activity sessions)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Weight-management camp
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Lifestyle education and activity phase
Number of subjects: 300
Study: 33926431

Group type: EXPERIMENTAL
Intervention: European countries
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-European countries
Number of subjects: 0
Study: 33926503

Group type: EXPERIMENTAL
Intervention: Watchful waiting
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Treatment indicated (surgery or targeted systemic therapy)
Number of subjects: 166
Study: 33926577

Group type: EXPERIMENTAL
Intervention: eScreening
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multicomponent implementation strategy (MCIS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Contextual factors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current screening methods (control)
Number of subjects: 0
Study: 33926797

Group type: EXPERIMENTAL
Intervention: Carbon nanoparticles (CNs) injection (0.3 mL) into the fusion node prior to NAC.
Number of subjects: 110
Study: 33926914

Group type: EXPERIMENTAL
Intervention: MORAb-202 (0.3 to 1.2 mg/kg intravenously once every three weeks)
Number of subjects: 22
Study: 33927105

Group type: EXPERIMENTAL
Intervention: HPI algorithm using noninvasive ABP measurements at an alarm threshold of 85
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: HPI algorithm using noninvasive ABP measurements at an alarm threshold of 75
Number of subjects: 507

Group type: COMPARATOR
Intervention: HPI algorithm using invasive ABP measurements
Number of subjects: 507
Study: 33927108

Group type: EXPERIMENTAL
Intervention: Next-generation sequencing (NGS)
Number of subjects: 0
Study: 33927586

Group type: EXPERIMENTAL
Intervention: Mobile chat-based support plus nicotine replacement therapy sampling (NRT-S)
Number of subjects: 119

Group type: COMPARATOR
Intervention: General smoking cessation text messages
Number of subjects: 119
Study: 33927680

Group type: EXPERIMENTAL
Intervention: Penumbra SMART COIL System
Number of subjects: 0
Study: 33927689

Group type: EXPERIMENTAL
Intervention: Autotitrating Bilevel Positive Airway Pressure (ABPAP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study: 33927885

Group type: EXPERIMENTAL
Intervention: Lifelong endurance athletes
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Late-onset endurance athletes
Number of subjects: 600

Group type: COMPARATOR
Intervention: Healthy non-athletes
Number of subjects: 600
Study: 33928400

Group type: EXPERIMENTAL
Intervention: FDG PET/CT
Number of subjects: 930

Group type: COMPARATOR
Intervention: Bone marrow biopsy (BMB)
Number of subjects: 930
Study: 33928414

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33928466

Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: YTHDF1 reintroduction via BBB-crossing viral delivery system
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prolonged anesthesia in children
Number of subjects: 0
Study: 33928713

Group type: EXPERIMENTAL
Intervention: Enhanced MARVEL 2 algorithm (VDD pacing mode)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Enhanced MARVEL 2 algorithm (VVI-40 mode)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Enhanced MARVEL 2 algorithm
Number of subjects: 73
Study: 33929089

Group type: EXPERIMENTAL
Intervention: Peficitinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33929327

Group type: EXPERIMENTAL
Intervention: eHealth tool for self-management strategies, accessed for 3 months.
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: eHealth tool after 12 months of access.
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: eHealth tool usage factors.
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Health literacy measured by the Communicative and Critical Health Literacy Scale.
Number of subjects: 16
Study: 33929337

Group type: EXPERIMENTAL
Intervention: Body Partner [Téfal]
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: DietPack [Terraillon]
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Body Cardio [Nokia Withings]
Number of subjects: 153
Study: 33929346

Group type: EXPERIMENTAL
Intervention: Respiratory Volume Monitor (RVM)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Respiratory Volume Monitor (RVM) with patient calibration
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Respiratory Volume Monitor (RVM) without patient calibration
Number of subjects: 40
Study: 33929361

Group type: EXPERIMENTAL
Intervention: Delirium present on a given day
Number of subjects: 1040

Group type: EXPERIMENTAL
Intervention: Hypoactive delirium
Number of subjects: 1040

Group type: EXPERIMENTAL
Intervention: Hyperactive delirium
Number of subjects: 1040

Group type: EXPERIMENTAL
Intervention: Delirium presence among hospital survivors
Number of subjects: 1040

Group type: EXPERIMENTAL
Intervention: Delirium duration among hospital survivors
Number of subjects: 1040
Study: 33929377

Group type: EXPERIMENTAL
Intervention: Risk assessment in the emergency department for very-low-risk patients (Glasgow-Blatchford score = 0-1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Red blood cell transfusion at a threshold of 7 g/dL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Erythromycin infusion before endoscopy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endoscopy within 24 hours after presentation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endoscopic therapy for ulcers with active spurting or oozing and for nonbleeding visible vessels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endoscopic therapy with bipolar electrocoagulation, heater probe, and absolute ethanol injection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clips, argon plasma coagulation, and soft monopolar electrocoagulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hemostatic powder spray TC-325
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Over-the-scope clips for recurrent ulcer bleeding after previous successful hemostasis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose proton pump inhibitor therapy continuously or intermittently for 3 days, followed by twice-daily oral proton pump inhibitor for the first 2 weeks after endoscopy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repeat endoscopy for recurrent bleeding
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transcatheter embolization if endoscopic therapy fails
Number of subjects: 0
Study: 33929394

Group type: EXPERIMENTAL
Intervention: Anti-PD-1 Inhibitor
Number of subjects: 0
Study: 33929496

Group type: EXPERIMENTAL
Intervention: Gained insurance
Number of subjects: 126699

Group type: EXPERIMENTAL
Intervention: Uninsured patients
Number of subjects: 126699

Group type: EXPERIMENTAL
Intervention: Post-ACA diagnosis
Number of subjects: 126699

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 126699
Study: 33929641

Group type: EXPERIMENTAL
Intervention: Ultrasonic cardiac output monitor (USCOM)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Echocardiography
Number of subjects: 127
Study: 33929686

Group type: EXPERIMENTAL
Intervention: Dabigatran (Cohort A)
Number of subjects: 9472

Group type: EXPERIMENTAL
Intervention: Dabigatran (Cohort B)
Number of subjects: 9472

Group type: COMPARATOR
Intervention: Dabigatran and VKAs (Cohort B)
Number of subjects: 9472

Group type: COMPARATOR
Intervention: VKAs (Cohort B)
Number of subjects: 9472
Study: 33929874

Group type: EXPERIMENTAL
Intervention: BKV-specific cytotoxic T lymphocytes (CTLs) infusion
Number of subjects: 59
Study: 33929895

Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan (SG) 10 mg/kg on days 1 and 8 of 21-day cycles
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan (SG)
Number of subjects: 113
Study: 33929935

Group type: EXPERIMENTAL
Intervention: Metagenomic next-generation sequencing
Number of subjects: 816
Study: 33930223

Group type: EXPERIMENTAL
Intervention: Single-tablet combination of sofosbuvir (400 mg) and daclatasvir (30, 60, or 90 mg) for 12 or 24 weeks
Number of subjects: 233
Study: 33930518

Group type: EXPERIMENTAL
Intervention: Fenestrated endovascular aneurysm repair (FEVAR)
Number of subjects: 124
Study: 33931404

Group type: EXPERIMENTAL
Intervention: Milder prolonged hypoglycemia (2.8 mmol/L for 1 hour) in control subjects
Number of subjects: 63

Group type: COMPARATOR
Intervention: Severe transient hypoglycemia (2.0 mmol/L transiently) in control subjects
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Milder prolonged hypoglycemia in T2D subjects
Number of subjects: 63

Group type: COMPARATOR
Intervention: Severe transient hypoglycemia in T2D subjects
Number of subjects: 63
Study: 33931857

Group type: EXPERIMENTAL
Intervention: Bitopertin, a glycine transport inhibitor, administered orally, dosage and duration not available.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified.
Number of subjects: 0
Study: 33931953

Group type: EXPERIMENTAL
Intervention: 300 mg allopurinol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clinical inhibitors of BCRP
Number of subjects: 0
Study: 33931973

Group type: EXPERIMENTAL
Intervention: Dietary intervention
Number of subjects: 0
Study: 33932113

Group type: EXPERIMENTAL
Intervention: LACE index (length of stay, acuity, Charlson co-morbidities, emergent visits)
Number of subjects: 1985

Group type: EXPERIMENTAL
Intervention: LE index (length of stay and emergent visits)
Number of subjects: 1985
Study: 33932130

Group type: EXPERIMENTAL
Intervention: Dabrafenib 150 mg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Midazolam 3 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rosuvastatin 10 mg
Number of subjects: 0
Study: 33932223

Group type: EXPERIMENTAL
Intervention: Insulin degludec (± prandial insulin)
Number of subjects: 626

Group type: COMPARATOR
Intervention: Other basal insulins (± prandial insulin)
Number of subjects: 626
Study: 33932502

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 0
Study: 33933036

Group type: EXPERIMENTAL
Intervention: Ambulatory oxygen therapy
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (age- and gender-matched from the general population)
Number of subjects: 42
Study: 33933087

Group type: EXPERIMENTAL
Intervention: Greater depressive symptoms during pregnancy (β ± SE = 0.03 ± 0.01, p < .01)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher stress during pregnancy (β ± SE = 0.03 ± 0.01, p < .01)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Worse sleep quality during pregnancy (β ± SE = 0.03 ± 0.01, p = 0.03)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Greater depressive symptoms during pregnancy (OR = 1.08, 95% CI: 1.02, 1.14, p = .01)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher stress during pregnancy (OR = 1.09, 95% CI: 1.04, 1.14, p < .01)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Worse sleep quality during pregnancy (OR = 1.09, 95% CI: 1.00, 1.18, p = .04)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Greater depressive symptoms during pregnancy (β ± SE = 0.06 ± 0.02, p < .01)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher stress during pregnancy (β ± SE = 0.04 ± 0.01, p < .01)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Worse sleep quality during pregnancy (β ± SE = 0.11 ± 0.03, p < .01)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased depressive symptoms from pregnancy to postpartum (β ± SE = 1.17 ± 0.57, p = 0.01)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased depressive symptoms from pregnancy to postpartum (0.88 ± 0.33, p = 0.01)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased stress from pregnancy to postpartum (1.71 ± 0.76, p = 0.02)
Number of subjects: 0
Study: 33933118

Group type: EXPERIMENTAL
Intervention: Intensity modulated radiotherapy (RT)
Number of subjects: 35
Study: 33933408

Group type: EXPERIMENTAL
Intervention: Pulmonary Valve Replacement (PVR)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Pulmonary Valve Replacement (PVR) before ICD implantation
Number of subjects: 165
Study: 33933412

Group type: EXPERIMENTAL
Intervention: Pulsed Field Ablation (PFA)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Pulsed Field Ablation (PFA) with optimized biphasic energy
Number of subjects: 121
Study: 33933689

Group type: EXPERIMENTAL
Intervention: Cognitive Orientation to Daily Occupational Performance (CO-OP) intervention, 14 individual sessions
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control goal (not trained)
Number of subjects: 2
Study: 33933719

Group type: EXPERIMENTAL
Intervention: First-episode antipsychotic-naïve patients with schizophrenia
Number of subjects: 36

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Combined analysis of patients and controls
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: First-episode antipsychotic-naïve patients with schizophrenia and Healthy controls
Number of subjects: 36
Study: 33933733

Group type: EXPERIMENTAL
Intervention: Dietary fiber intake
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Total dietary fiber, insoluble, soluble dietary fiber, and galacto-oligosaccharide intakes
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Soluble dietary fiber intake
Number of subjects: 50
Study: 33933895

Group type: EXPERIMENTAL
Intervention: HFRT-CHT using IMRT technique (51 Gy in 17 fractions or 40 Gy in 10 fractions followed by a boost of 15 Gy in 5 fractions or 28 Gy in 7 fractions)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: HFRT-CHT using IMRT technique
Number of subjects: 58
Study: 33933925

Group type: COMPARATOR
Intervention: Conventional fractionated radiation therapy (CFRT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postmastectomy hypofractionated radiation therapy (HFRT)
Number of subjects: 0
Study: 33934110

Group type: EXPERIMENTAL
Intervention: Pittsburgh Compound-B (PiB) imaging
Number of subjects: 0
Study: 33934200

Group type: EXPERIMENTAL
Intervention: Choline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: L-carnitine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Betaine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: γ-butyrobetaine (γ-BB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3,3-Dimethyl-1-butanol (DMB)
Number of subjects: 0
Study: 33934351

Group type: EXPERIMENTAL
Intervention: MIV-mono (mivebresib at doses of 1.5, 2.0, or 2.5 mg)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: MIV-Ven (mivebresib in combination with venetoclax at doses of 400 or 800 mg)
Number of subjects: 44
Study: 33934706

Group type: EXPERIMENTAL
Intervention: Allergic conjunctivitis (AC) group
Number of subjects: 50